Through advances in surgical techniques, organ donation, and immunosuppression, liver transplantation (LT) recipients have expected 1-and 5-year survival rates >90% and 70%, respectively. (1) However, posttransplant immunosuppression is associated with a number of adverse effects and comorbidities, including diabetes mellitus. Furthermore, hepatitis C virus (HCV) infection independently has been associated with insulin resistance and diabetes mellitus. (2)(3)(4) Over the last decade, posttransplant diabetes mellitus (PTDM) has been increasingly recognized as a complication of solid organ transplantation associated with serious morbidity in LT recipients, particularly in patients with HCV infection. (5, 6) PTDM has previously been identified as an independent risk factor for mortality, graft failure, and rOccarO et al.
Through advances in surgical techniques, organ donation, and immunosuppression, liver transplantation (LT) recipients have expected 1-and 5-year survival rates >90% and 70%, respectively. (1) However, posttransplant immunosuppression is associated with a number of adverse effects and comorbidities, including diabetes mellitus. Furthermore, hepatitis C virus (HCV) infection independently has been associated with insulin resistance and diabetes mellitus. (2) (3) (4) Over the last decade, posttransplant diabetes mellitus (PTDM) has been increasingly recognized as a complication of solid organ transplantation associated with serious morbidity in LT recipients, particularly in patients with HCV infection. (5, 6) PTDM has previously been identified as an independent risk factor for mortality, graft failure, and cardiovascular events. (7) (8) (9) However, these associations have been inconsistent because few investigations of the prognostic impact of PTDM have distinguished de novo PTDM from pre-LT diabetes mellitus persisting after LT. Prior work by our group demonstrated that sustained posttransplant diabetes mellitus (s-PTDM), a persistent state of de novo hyperglycemia related to pancreatic β-cell dysfunction and insulin resistance, is associated with death and major cardiovascular events following LT. (7, 10) In contrast, transient PTDM, a state of hyperglycemia related to stress response and glucocorticoids, had no association with mortality or major cardiovascular events. (10) Several prior studies have demonstrated an association between PTDM and chronic HCV infection. (8, (11) (12) (13) In addition, cross-sectional, prospective longitudinal studies and a meta-analysis have associated HCV infection with an increased risk of type 2 diabetes mellitus. (3, 4, 14, 15) Further strengthening this association, Kawaguchi et al. demonstrated reversibility of derangements in glucose metabolism in a cohort of HCV patients treated with interferon-based therapy, in which insulin resistance improved following viral clearance. (2) With the introduction of safe and highly effective direct-acting antiviral (DAA) therapy for HCV infection, viral eradication prior to hepatic decompensation or soon after LT is now standard of care. (16) Although viral eradication may improve insulin resistance and glucose metabolism, it is unclear if the incidence of s-PTDM is altered by viral eradication. In this study, we used a contemporary single-center cohort of LT recipients to compare the incidence of s-PTDM among patients with HCV-related chronic liver disease with sustained virological response (SVR) as a time-varying exposure. We hypothesized that SVR is associated with a decreased risk of s-PTDM in LT recipients with HCV cirrhosis.
Patients and Methods
After approval from the University of Pennsylvania institutional review board, data were obtained from the Penn Data Store, a data repository that supplies clinical, administrative, and pharmacy data through an automated extraction of data elements from multiple patient record systems within the health network. This retrospective cohort study used an assembled cohort of adult (>18 years of age) patients with HCV cirrhosis who underwent LT at the hospital of the University of Pennsylvania from January 1, 2010 to June 30, 2015. Patients entered the cohort on the date of LT. They were censored from the analysis on the date of their last inpatient or outpatient encounter, date of death, or on the study end date of December 31, 2016.
We excluded patients with a history of DM prior to LT. Multiorgan recipients and patients with a solid organ or hematopoietic stem cell transplant prior to the date of LT were excluded due to their propensity to receive immunosuppressive regimens, which differ from the standard regimen used in LT recipients at our institution, as more intensive immunosuppressive regimens and prolonged glucocorticoid exposure may confer an increased risk of PTDM. Finally, LT recipients with <6 months of post-LT follow-up were excluded due to the inability to adequately assess their posttransplant diabetes status. At our institution, single-organ LT recipients are treated with a relatively homogeneous immunosuppressive regimen-combination therapy with tacrolimus and prednisone immediately following LT followed by tapering and cessation of prednisone over the ensuing 3-6-month period. In addition, induction is not used, and the decision to add a second immunosuppressive agent, such as mycophenolate mofetil or azathioprine, is individualized on the basis of etiology of liver failure, renal function, and prior episodes of rejection.
SVR was ascertained though a manual chart review and was treated as a discrete time-varying exposure, meaning patients may only change exposure once. A patient achieved SVR on the date of the first undetectable HCV RNA at least 12 weeks after completing anti-HCV therapy. Patients who achieved SVR prior to LT entered the cohort as "post-SVR." Data from our specialty pharmacy were used to confirm dates of HCV therapy initiation and completion. Other recipient factors and covariates collected included sex, age at LT, antiviral medications used, HCV genotype, body mass index (BMI) at LT, Model for End-Stage Liver
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Disease (MELD) score at LT, hepatocellular carcinoma (HCC) on explant, living versus deceased donor LT, and calcineurin inhibitor (CNI) use on discharge following LT. Acute cellular rejection (ACR) was ascertained on the date of a liver biopsy demonstrating ACR and the number of rejection episodes per patient was recorded.
The primary outcome was a diagnosis of s-PTDM, defined as de novo diabetes mellitus of at least 6 months duration following LT. (10) Diabetes mellitus was diagnosed according to the American Diabetes Association definition (hemoglobin A1c > 6.5%, fasting plasma glucose ≥ 126 mg/dL, a 2-hour plasma glucose level of ≥ 200 mg/dL or higher during a 75-g oral glucose tolerance test, a random plasma glucose of 200 mg/dL or higher on 2 occasions, or requiring medication for the management of hyperglycemia). (17) Patient survival, defined as the time from LT to death of any cause, was a secondary outcome.
Baseline clinical and demographic characteristics were summarized by medians and interquartile ranges (IQRs) for continuous variables or n (%) for categorical variables. Comparisons among patients with and without SVR at the time of LT were performed using chi-square and Kruskal-Wallis tests, when appropriate. Univariate and multivariate Cox proportional hazards models were used to compare crude and adjusted time to s-PTDM by time-varying SVR status. A comprehensive list of demographic and clinical variables was tested for association with s-PTDM and included in the multivariate Cox model if P <0. 15 . In addition, we included a priori-selected demographic and clinical characteristics associated with s-PTDM: age at LT, sex, race, BMI at LT, and ACR events. These methods were repeated to explore associations between SVR, s-PTDM, and patient survival. Following the multivariate Cox proportional hazards model, the adjusted s-PTDM-free survival and overall survival curves were plotted by SVR status. We tested Schoenfeld residuals to determine if the proportional hazards assumption was upheld. Two-sided P values <0.05 were considered statistically significant. Analyses were performed using STATA statistical software, version 14.0 (StataCorp, College Station, TX).
Results
From January 1, 2010 to December 31, 2015, 352 patients with HCV cirrhosis underwent LT (Fig. 1) . A total of 96 patients were excluded (67 patients with pre-LT diabetes mellitus, 16 patients with dual organ transplants, 7 patients with a prior solid organ transplant, and 6 patients with inadequate follow-up time). There were 256 eligible patients who were analyzed with a median follow-up time of 41.2 months (range 7.6-83.9 months).
Baseline patient demographic and clinical characteristics at cohort entry are displayed in Table 1 . The median age at LT was 59 years (IQR, 54-63 years). The median physiologic MELD score at LT was 17 (IQR, 12-25). Most patients had HCV genotype 1 infection (82.8%), and 167 (65.2%) patients had HCC on explant. All patients were prescribed a CNI on discharge following LT. There were 31 (12.1%) patients who achieved SVR prior to LT at a median time of 7 months prior to LT (IQR, 1-30 months). An additional 178 (69.5%) patients achieved SVR following LT at a median time of 23 months (IQR, 10-43 months) after LT. Of those who were viremic at LT, 26.4% (47/178) achieved SVR in the first post-LT year. Patients who achieved SVR following LT had a higher median MELD score at LT, were less likely to have HCC on explant pathology, and were more likely to have received DAA therapy than those who achieved SVR before LT (Table 1) .
During follow-up, 71 (27.7%) patients developed s-PTDM. Median time to the onset of de novo diabetes mellitus was 18 days (IQR, 9-28 days) post LT. All patients with s-PTDM required insulin for at least 6 months. Only 3/71 (4.2%) patients were eventually able to discontinue all glucose-lowering therapies. This occurred at 11, 17, and 26 months following LT.
Timing of viral eradication had an impact on the risk of s-PTDM. Of the 31 patients who achieved SVR prior to LT, 3 (9.7%) developed s-PTDM. In comparison, patients who were viremic at LT were more likely to develop s-PTDM (68/225; chi-square = 5.74; P = 0.02). In univariate Cox regression, pre-LT SVR was associated with a reduced risk of s-PTDM (hazard ratio [HR], 0.30; P = 0.046). Following adjustment for pertinent potential confounders present at the time of LT, including age, sex, race/ethnicity, BMI, MELD, and presence of HCC, pre-LT SVR maintained a trend toward reduced incidence of s-PTDM (HR, 0.36; P = 0.09). Of the 225 patients who were viremic at LT, 178 (79.1%) achieved SVR during the follow-up period, but 41 (23.0%) patients developed s-PTDM prior to SVR. Only 3 of the remaining 137 (2.2%) patients developed s-PTDM following SVR (Fig. 1) .
Furthermore, when excluding the 31 patients who had achieved SVR prior to LT, patients with SVR in the first post-LT year had a trend toward reduced risk of s-PTDM (HR, 0.50; P = 0.06).
In unadjusted analysis, Hispanic ethnicity, MELD score at LT, and SVR were associated with a reduced risk of s-PTDM (Table 2) . A Cox multivariate regression model, with a priori-selected covariables and variables with P < 0.15 in the univariate analysis, was fit (Table 2) . Variables included in the model were sex, race/ethnicity, age at LT, BMI at LT, ACR, SVR, and MELD score at LT (P < 0.15 in the univariate analysis). SVR was independently associated with a significantly reduced risk of s-PTDM (HR, 0.40; P = 0.048). Hispanic ethnicity was the only other variable found to be independently associated with s-PTDM (HR, 2.78; P = 0.01). The Cox adjusted s-PTDM free survival by SVR status is depicted in Fig. 2 . The 1-, 3-, and 5-year cumulative incidence rates of s-PTDM were 8.1%, 9.6%, and 11.7% and 18.4%, 21.4%, and 25.1% for patients with and without SVR, respectively. Schoenfeld residuals indicate that the assumption of proportional hazards was not violated (P = 0.15).
A total of 34 (13.3%) patients died during follow-up. Hispanic ethnicity (HR, 3.04; P = 0.048), African American race (HR, 2.42; P = 0.02), and MELD score at LT (HR, 1.05; P = 0.01) were associated with mortality, whereas HCC on explant (HR, 0.48; P = 0.03) and SVR (HR, 0.30; P = 0.01) were all associated with a survival benefit. There was a trend toward increased risk of death in patients with s-PTDM (HR, 1.91; P = 0.07). Following Cox multivariate regression model adjusting for a priori selected covariables (sex, age, race/ethnicity, and BMI) and variables with P < 0.15 in the univariate analysis, SVR was the only variable independently associated with post-LT survival (HR, 0.38; P = 0.04). The Cox adjusted overall survival by SVR status is illustrated in Fig. 3 . 
Discussion
The advent of DAA therapy for HCV has revolutionized the landscape of LT for HCV-related chronic liver disease. Since the introduction of DAA therapy, there has been a significant decline in the number and percentage of LT wait-list registrants with HCV cirrhosis and percentage of LT surgeries performed for HCV. (18, 19) Post-LT SVR rates have risen from approximately 25% with interferon-based therapy to >90% with DAA. (20, 21) By preventing the rapid progression of liver fibrosis associated with post-LT HCV infection, we will undoubtedly witness improvement in graft and patient survival for LT recipients with HCV.
Although the benefits of SVR in a posttransplant population may no longer be disputed, the impact of SVR on posttransplant metabolic complications is of interest. We explored the association of HCV viral eradication with the incidence of s-PTDM, a major comorbidity following solid organ transplantation with few known modifiable risk factors. This large single-center cohort study allowed the unique opportunity to use granular data to carefully examine variables that could affect the incidence of s-PTDM in a period spanning the introduction of DAA therapy, data that are lacking in larger data sets such as United Network for Organ Sharing/Organ Procurement Transplant Network. Original article | 1671
We compared the incidence of s-PTDM among LT recipients with HCV-related cirrhosis and no prior history of diabetes mellitus using SVR as a time varying exposure. We observed that viral clearance was independently associated with a significantly reduced risk of s-PTDM and death. Timing of SVR plays an intricate role in this association. Pre-LT SVR, which was associated with a 70% reduction in the risk of s-PTDM in univariate analysis, appeared to have a significant influence on the development of de novo diabetes mellitus early after transplant. This is illustrated by the rapid divergence in the estimated s-PTDMfree survival curves in Fig. 2B . Although the benefit of pre-LT SVR on s-PTDM was more evident, there also seemed to be an advantage to early post-LT SVR. Of those viremic at transplant, SVR in the first post-LT year was associated with a trend toward a reduced risk of s-PTDM.
This single-center study has several strengths. First, we have robust data with longterm follow-up of more than 250 LT recipients over a period of time in which DAA use became standard of care. Second, use of automated data extraction techniques from the health system data warehouse allowed use of granular data elements, including inpatient and outpatient encounter diagnoses, procedures codes, laboratory results, and medications prescribed. This facilitated a rigorous characterization of each patient's diabetes status according to the standard definition of the World Health Organization/American Diabetes Association, reducing the risk of misclassification which commonly occurs when using large registry data and allowing for differentiation between transient hyperglycemia following LT and s-PTDM. Finally, by using a time-varying definition for SVR, we could accurately establish a temporal relationship between the exposure of interest and the outcome.
The results presented should be interpreted with some limitations in mind. Use of SVR at 12 weeks as a surrogate for viral eradication, rather than actual HCV RNA quantification, may impart up to 24 weeks of potential misclassified time for patients on HCV therapy in which they are classified as "viremic" because SVR has not yet been achieved despite actual viral clearance shortly after initiating DAA therapy. However, if HCV eradication does indeed decrease the risk of s-PTDM, this misclassified period from the time of actual viral clearance to the observation of SVR at 12 weeks would bias the results toward the null hypothesis. Second, although we were able to adjust for the number of ACR events, which may account for some heterogeneity in immunosuppressive therapy, our database lacked consistent longitudinal patient data on immunosuppressive management. Nonetheless, we do not think that this biases our findings substantially because being a single-center study, single-organ LT recipients are treated in a relatively homogeneous manner. This is demonstrated by 100% of the cohort receiving a CNI on discharge following the transplant episode. Finally, as we did not have data pertaining to hemoglobin A1c, we could not discern the association between HCV therapy and glucose homeostasis in those patients who developed s-PTDM prior to viral eradication.
In summary, in this large single-center experience, we have demonstrated s-PTDM to be a common complication following LT in patients with HCV. SVR is associated with a reduced risk of s-PTDM, independent of other classic risk factors for PTDM, including age, sex, race and ethnicity, BMI, and number of ACR episodes. Timing of SVR likely plays a vital role in risk reduction with pre-LT SVR having the most biologically plausible influence on post-LT de novo diabetes. HCV, a consistently reported risk factor for PTDM, is one of the only modifiable risk factors for s-PTDM. These findings indicate a potential nongraft-related benefit to pretransplant HCV therapy. However, this benefit must be appraised in the context of factors that influence the probability of the patient successfully undergoing LT, namely, long wait time, MELD score, and the availability and use of HCV-positive grafts in a given region. At this time, further investigations in larger and more contemporary cohorts are needed to confirm these findings and to investigate the impact of early HCV eradication on other posttransplant outcomes, including renal function, graft rejection, and components of the metabolic syndrome. 
